- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Jagsonpal Pharmaceuticals began FY26 strongly, with Q1 revenue up 23.1% YoY to ₹75.6 Cr and EBITDA growing 24.1% to ₹15.7 Cr (20.8% margin). Net profit more than doubled to ₹10.8 Cr (14.3% margin), driven by strong brand equity and operational execution. Gross margins improved to 64.4%. The company added ₹15.3 Cr in free cash, bringing total cash to ₹160.9 Cr. Management expects continued domestic growth and will seek strategic inorganic opportunities, highlighting a confident outlook and improved Gynae CVM ranking to #7.